FMS Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 3.1% compared to Fresenius Medical Care AG's net margin of -227.46%. Fresenius Medical Care AG's return on equity of 4.05% beat BioNTech SE's return on equity of -3.91%.

Fresenius Medical Care AG has a consensus price target of $31.05, signalling upside risk potential of 10.06%. On the other hand BioNTech SE has an analysts' consensus of $136.46 which suggests that it could grow by 27.87%. Given that BioNTech SE has higher upside potential than Fresenius Medical Care AG, analysts believe BioNTech SE is more attractive than Fresenius Medical Care AG.

Fresenius Medical Care AG has a beta of 0.882, which suggesting that the stock is 11.825% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 2.89%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.1B, which are larger than BioNTech SE quarterly revenues of $192.3M. Fresenius Medical Care AG's net income of $159.1M is higher than BioNTech SE's net income of -$437.5M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 24.70x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.79x versus 8.65x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of 3.1% compared to Fresenius Medical Care AG's net margin of -5832.47%. Fresenius Medical Care AG's return on equity of 4.05% beat CureVac NV's return on equity of 32.68%.

Fresenius Medical Care AG has a consensus price target of $31.05, signalling upside risk potential of 10.06%. On the other hand CureVac NV has an analysts' consensus of $4.27 which suggests that it could fall by -20.63%. Given that Fresenius Medical Care AG has higher upside potential than CureVac NV, analysts believe Fresenius Medical Care AG is more attractive than CureVac NV.

Fresenius Medical Care AG has a beta of 0.882, which suggesting that the stock is 11.825% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 2.89%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.1B, which are larger than CureVac NV quarterly revenues of $939.6K. Fresenius Medical Care AG's net income of $159.1M is higher than CureVac NV's net income of -$54.8M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 24.70x while CureVac NV's PE ratio is 5.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.79x versus 2.10x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Merck KGaA has a net margin of 3.1% compared to Fresenius Medical Care AG's net margin of 13.92%. Fresenius Medical Care AG's return on equity of 4.05% beat Merck KGaA's return on equity of 9.69%.

Fresenius Medical Care AG has a consensus price target of $31.05, signalling upside risk potential of 10.06%. On the other hand Merck KGaA has an analysts' consensus of $35.10 which suggests that it could grow by 33.31%. Given that Merck KGaA has higher upside potential than Fresenius Medical Care AG, analysts believe Merck KGaA is more attractive than Fresenius Medical Care AG.

Fresenius Medical Care AG has a beta of 0.882, which suggesting that the stock is 11.825% less volatile than S&P 500. In comparison Merck KGaA has a beta of 0.957, suggesting its less volatile than the S&P 500 by 4.302%.

Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 2.89%. Merck KGaA offers a yield of 1.9% to investors and pays a quarterly dividend of $0.50 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. Merck KGaA pays out 10.23% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.1B, which are smaller than Merck KGaA quarterly revenues of $5.6B. Fresenius Medical Care AG's net income of $159.1M is lower than Merck KGaA's net income of $773.4M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 24.70x while Merck KGaA's PE ratio is 18.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.79x versus 2.50x for Merck KGaA. Usually stocks with elevated PS ratios are considered overvalued.

Siemens Healthineers AG has a net margin of 3.1% compared to Fresenius Medical Care AG's net margin of 8.97%. Fresenius Medical Care AG's return on equity of 4.05% beat Siemens Healthineers AG's return on equity of 11.11%.

Fresenius Medical Care AG has a consensus price target of $31.05, signalling upside risk potential of 10.06%. On the other hand Siemens Healthineers AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Fresenius Medical Care AG has higher upside potential than Siemens Healthineers AG, analysts believe Fresenius Medical Care AG is more attractive than Siemens Healthineers AG.

Fresenius Medical Care AG has a beta of 0.882, which suggesting that the stock is 11.825% less volatile than S&P 500. In comparison Siemens Healthineers AG has a beta of 0.996, suggesting its less volatile than the S&P 500 by 0.38%.

Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 2.89%. Siemens Healthineers AG offers a yield of 3.66% to investors and pays a quarterly dividend of $0.50 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. Siemens Healthineers AG pays out 54.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.1B, which are smaller than Siemens Healthineers AG quarterly revenues of $6.2B. Fresenius Medical Care AG's net income of $159.1M is lower than Siemens Healthineers AG's net income of $557.7M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 24.70x while Siemens Healthineers AG's PE ratio is 27.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.79x versus 2.47x for Siemens Healthineers AG. Usually stocks with elevated PS ratios are considered overvalued.